Showing 1121-1130 of 1572 results for "".
- Harnessing Dual Capabilities of the Immune System in Oncology and Allergyhttps://reachmd.com/news/harnessing-dual-capabilities-of-the-immune-system-in-oncology-and-allergy/2476046/Harnessing the immune system’s dual capabilities—tearing down tumors and correcting allergic misfires—is redefining therapeutic paradigms across specialties. Recent breakthroughs show that metabolic interventions can reinvigorate exhausted T cells in oncology while antigen-specific delivery
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://reachmd.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Harnessing AI and Preventive Surgery to Transform Breast Cancer Carehttps://reachmd.com/news/harnessing-ai-and-preventive-surgery-to-transform-breast-cancer-care/2475866/Emerging AI platforms are being developed to enhance the precision of targeting cancer cells, while expanding preventive surgical options may reduce breast cancer incidence in high-risk women. Oncologists today must navigate the integration of advanced artificial intelligence tools w
- Evolving Strategies for Treating Advanced NSCLC in Elderly Patients: The Role of PD-1/PD-L1 Inhibitorshttps://reachmd.com/news/evolving-strategies-for-treating-advanced-nsclc-in-elderly-patients-the-role-of-pd-1pd-l1-inhibitors/2475843/Managing advanced non-small cell lung cancer in patients over 70 presents a therapeutic paradox: how to harness immunotherapy’s power without tipping the balance toward intolerable toxicity. Oncologists face mounting evidence that elderly NSCLC treatment requires greater nuance than
- Nanoparticle Innovations in Cancer Therapy: Precision and Challengeshttps://reachmd.com/news/nanoparticle-innovations-in-cancer-therapy-precision-and-challenges/2475828/Precision in tumor targeting remains a critical unmet need in oncology, as systemic therapies often damage healthy tissue and fall short of eradicating malignant cells. Against this backdrop, innovations in nanoparticle-based drug delivery systems are gaining momentum.
- DLL3 Expression: Diagnostic and Therapeutic Implications in Neuroendocrine Neoplasmshttps://reachmd.com/news/dll3-expression-diagnostic-and-therapeutic-implications-in-neuroendocrine-neoplasms/2475630/Delta-like ligand 3 (DLL3) has become a focal point in the evolving landscape of targeted therapies for neuroendocrine neoplasms (NEN), especially given its established role in pulmonary small cell neuroendocrine carcinoma (SCNEC). As a Notch pathway ligand aberrantl
- DNA Methylation Patterns: Enhancing Diagnosis and Treatment Precision in Childhood Leukemiahttps://reachmd.com/news/dna-methylation-patterns-enhancing-diagnosis-and-treatment-precision-in-childhood-leukemia/2474816/Cutting-edge developments in Pediatrics and Genetics have unveiled novel diagnostic approaches for childhood leukemia. Evaluating DNA methylation patterns in leukemic cells offers a more precise approach to risk assessment, leading to more targeted and safer therap
- HER3 and Cancer Progression: Investigating Mechanisms of Therapy Resistancehttps://reachmd.com/news/her3-and-cancer-progression-investigating-mechanisms-of-therapy-resistance/2474612/The rediscovery of HER3 as a crucial player in cancer progression has transformed our understanding of tumor biology. Previously eclipsed by other ErbB receptors, HER3 is recognized for its intricate signaling networks that spur therapy resistance and foster cell s
- Targeted Therapy: Zongertinib in HER2-Mutant Lung Cancer Clinical Evaluationhttps://reachmd.com/news/targeted-therapy-zongertinib-in-her2-mutant-lung-cancer-clinical-evaluation/2474373/In the relentless pursuit of precision medicine, the treatment landscape for non-small cell lung cancer (NSCLC) continues to evolve, offering new hope to patients who previously faced limited options. Recent findings from the Beamion LUNG-1 trial signal a major ste
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://reachmd.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na